Literature DB >> 23481145

Guideline for management of postmeal glucose in diabetes.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23481145     DOI： 10.1016/j.diabres.2012.08.002

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


× No keyword cloud information.
  28 in total

1.  Metabolic perturbations of post-load hyperglycemia vs. fasting hyperglycemia.

Authors:  Jing-Yi Lu; Jia-Hui Peng; Xiao-Jing Ma; Yi-Nan Zhang; Wei Zhu; Xing-Xing He; Ling-Wen Ying; Yu-Qian Bao; Jian Zhou; Wei-Ping Jia
Journal:  Acta Pharmacol Sin       Date:  2018-05-17       Impact factor: 6.150

2.  Oxidative Stress Alterations in the Bladder of a Short-period Type 2 Diabetes Rat Model: Antioxidant Treatment Can Be Beneficial for the Bladder.

Authors:  Panagiota Tsounapi; Masashi Honda; Katsuya Hikita; Nikolaos Sofikitis; Atsushi Takenaka
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

Review 3.  Gut-Based Strategies to Reduce Postprandial Glycaemia in Type 2 Diabetes.

Authors:  Md Kamruzzaman; Michael Horowitz; Karen L Jones; Chinmay S Marathe
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-09       Impact factor: 5.555

4.  Glycaemic Profiles of Children With Overweight and Obesity in Free-living Conditions in Association With Cardiometabolic Risk.

Authors:  Jesse Rijks; Kylie Karnebeek; Jan-Willem van Dijk; Elke Dorenbos; Willem-Jan Gerver; Pauline Stouthart; Jogchum Plat; Anita Vreugdenhil
Journal:  Sci Rep       Date:  2016-08-18       Impact factor: 4.379

5.  Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.

Authors:  T Heise; U Hövelmann; L Brøndsted; C L Adrian; L Nosek; H Haahr
Journal:  Diabetes Obes Metab       Date:  2015-05-08       Impact factor: 6.577

6.  The Effect of a Breakfast Rich in Slowly Digestible Starch on Glucose Metabolism: A Statistical Meta-Analysis of Randomized Controlled Trials.

Authors:  Sophie Vinoy; Alexandra Meynier; Aurélie Goux; Nathalie Jourdan-Salloum; Sylvie Normand; Rémi Rabasa-Lhoret; Olivier Brack; Julie-Anne Nazare; François Péronnet; Martine Laville
Journal:  Nutrients       Date:  2017-03-23       Impact factor: 5.717

7.  Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.

Authors:  Chantal Mathieu; Bruce W Bode; Edward Franek; Athena Philis-Tsimikas; Ludger Rose; Tina Graungaard; Anne Birk Østerskov; David Russell-Jones
Journal:  Diabetes Obes Metab       Date:  2018-02-04       Impact factor: 6.577

8.  Comparative effects of insulin glulisine and lispro on postprandial plasma glucose and lipid profile in Japanese patients with type 2 diabetes mellitus.

Authors:  Mika Yamada; Jinya Suzuki; Takahiro Nakaya; Mai Ichikawa; Katsushi Yamamoto; Michiko Imagawa; Satsuki Sato; Miki Fujii; Yasuo Zenimaru; Tadashi Konoshita; Tamotsu Ishizuka
Journal:  Diabetol Int       Date:  2020-11-17

Review 9.  Forum for Injection Technique and Therapy Expert Recommendations, India: The Indian Recommendations for Best Practice in Insulin Injection Technique, 2017.

Authors:  Nikhil Tandon; Sanjay Kalra; Yatan Pal Singh Balhara; Manash P Baruah; Manoj Chadha; Hemraj B Chandalia; K M Prasanna Kumar; S V Madhu; Ambrish Mithal; Rakesh Sahay; Rishi Shukla; Annamalai Sundaram; Ambika G Unnikrishnan; Banshi Saboo; Vandita Gupta; Subhankar Chowdhury; Jothydev Kesavadev; Subhash K Wangnoo
Journal:  Indian J Endocrinol Metab       Date:  2017 Jul-Aug

10.  Efficacy and safety of switching from basal insulin to once-daily insulin degludec/insulin aspart in Japanese patients with inadequately controlled type 2 diabetes: A 4-week, randomized, open-label, treat-to-target study.

Authors:  Yoshio Nagai; Ami Nishine; Eriko Hashimoto; Taiga Nakayama; Yosuke Sasaki; Mariko Murakami; Satoshi Ishii; Hiroyuki Kato; Yasushi Tanaka
Journal:  J Diabetes Investig       Date:  2017-09-16       Impact factor: 4.232
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.